Jointly sponsored by Medical Education Collaborative (MEC) and Princeton CME
Purpose Statement
This activity is designed to educate managed markets physicians and pharmacists on current evidence-based approaches for the management of allergic rhinitis to improve patient quality of life and minimize healthcare resource use.
Target Audience
Managed markets physicians and pharmacists, including medical directors, pharmacy directors, formulary directors, and consultant pharmacists.
Learning Objectives
After completing this activity, participants should be able to:
- Define the impact of allergic rhinitis, as a chronic inflammatory condition, on patient quality of life and healthcare costs
- Summarize the frequent complications and comorbidities of allergic rhinitis and the effect on the burden of disease
- Outline the evidence for the benefits and limitations of available medications for the management of allergic rhinitis
- Utilize current data to make evidence-based formulary decisions, develop algorithms, and maximize outcomes in allergic rhinitis
Credit Eligibility
To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release date: December 13, 2007; Expiration date: December 28, 2008
Estimated time to complete: 1 hour
There is no fee associated with this activity.
Lecture Components
The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and Princeton CME. MEC is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Collaborative designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding the ACCME accreditation of this activity, please contact Medical Education Collaborative at 866.420.3252
CPE Accreditation
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN #452-999-07-033-H01).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.
Grant Support
Supported by an educational grant from Schering-Plough Corporation
Participating Faculty
Michael S. Blaiss, MD
Clinical Professor of Pediatrics and Medicine
University of Tennessee Health Science Center
Memphis, Tennessee
Elena Umland, PharmD
Associate Dean for Academic Affairs
Associate Professor of Clinical Pharmacy
Jefferson School of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Independent Clinical Reviewer
Javed Sheikh, MD
Clinical Director
Division of Allergy and Inflammation
Beth Israel Deaconess Medical Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of MEC and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of MEC and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Blaiss: Advisory board — Alcon, Inc., Astra Zeneca, GlaxoSmithKline, Merck, Sanofi-Aventis, Schering-Plough Corporation, Teva Pharmaceuticals; Speakers Bureau — Alcon, Inc., Astra Zeneca, GlaxoSmithKline, Inspire Pharmaceuticals, Merck, Sanofi-Aventis, Schering-Plough Corporation, Teva Pharmaceuticals.
Dr. Sheikh: Research Support— GlaxoSmithKline; Speakers Bureau — Genentech, MedPointe Pharmaceuticals, Novartis, Sanofi-Aventis, UCB Pharmaceuticals.
Dr. Umland disclosed no relevant financial relationships with any commercial interests.
Planning Committee employees of MEC, the accredited provider for this activity; Randy Robbin and John Savage, Princeton CME; and Angela Merckling and Rosemary Hodgson, Princeton Media Communications have disclosed that they have no relevant financial relationships with any commercial interest.
MEC and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.
The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.
